Image of Gail H Cassell

Gail H Cassell, Ph.D.

Dr. Cassell is vice president for TB Drug Development at the Infectious Disease Research Institute in Seattle, Washington, professor emeritus and former chair, Department of Microbiology, University of Alabama at Birmingham, and former vice president for scientific affairs and distinguished Lilly research scholar for infectious diseases at Eli Lilly and Company in Indianapolis, Indiana. She founded the Forum on Drug Discovery, Development and Translation, which she continues to co-chair, at the Institute of Medicine. She has a distinguished record of national service with the National Academy of Sciences, National Institutes of Health, Centers for Disease Control, and several other national and international institutions.

Affiliations:

Division of Global Health Equity, Brigham and Women's Hospital

Dr. Cassell is a leader on efforts to address multidrug-resistant tuberculosis (MDRTB). She and Barry Bloom, former dean of Harvard School of Public Health, co-lead an Institute of Medicine project on drug supply chain issues related to MDRTB. She actively advises numerous government agencies, NGOs, and foundations on the scale-up of MDRTB diagnosis and treatment in endemic areas around the world, including in Russia. Dr. Cassell is advising the GHSM Sentinel Project on pediatric drug-resistant tuberculosis, a global partnership that aims to develop and deploy evidence-based strategies to prevent child deaths from drug-resistant tuberculosis.

Upper respiratory tract is the major site of antibody production in mycoplasmal induced chronic respiratory disease.
Authors: Authors: Simecka JW, Patel P, Davis JK, Cassell GH.
Reg Immunol
View full abstract on Pubmed
Mycoplasma hominis septic thrombophlebitis in a patient with multiple trauma: a case report and literature review.
Authors: Authors: Martinez OV, Chan J, Cleary T, Cassell GH.
Diagn Microbiol Infect Dis
View full abstract on Pubmed
In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.
Authors: Authors: Waites KB, Cassell GH, Canupp KC, Fernandes PB.
Antimicrob Agents Chemother
View full abstract on Pubmed
Adsorption of mycoplasma virus P1 to host cells.
Authors: Authors: Dybvig K, Alderete J, Watson HL, Cassell GH.
J Bacteriol
View full abstract on Pubmed
Differences in virulence for mice among strains of Mycoplasma pulmonis.
Authors: Authors: Davidson MK, Lindsey JR, Parker RF, Tully JG, Cassell GH.
Infect Immun
View full abstract on Pubmed
Role of Ureaplasma urealyticum and other pathogens in the development of chronic lung disease of prematurity.
Authors: Authors: Wang EE, Frayha H, Watts J, Hammerberg O, Chernesky MA, Mahony JB, Cassell GH.
Pediatr Infect Dis J
View full abstract on Pubmed
Natural mycoplasmal infections in isolator-maintained LEW/Tru rats.
Authors: Authors: Cox NR, Davidson MK, Davis JK, Lindsey JR, Cassell GH.
Lab Anim Sci
View full abstract on Pubmed
Does Ureaplasma urealyticum cause respiratory disease in newborns?
Authors: Authors: Cassell GH, Crouse DT, Waites KB, Rudd PT, Davis JK.
Pediatr Infect Dis J
View full abstract on Pubmed
Clearance of different strains of Mycoplasma pulmonis from the respiratory tract of C3H/HeN mice.
Authors: Authors: Davidson MK, Davis JK, Lindsey JR, Cassell GH.
Infect Immun
View full abstract on Pubmed
Colony opacity, hemadsorption, hemolysis, and mitogenicity are not associated with virulence of Mycoplasma pulmonis.
Authors: Authors: Davidson MK, Ross SE, Lindsey JR, Cassell GH.
Infect Immun
View full abstract on Pubmed